http://purl.org/np/RASraUVoS8... RASraUVoS8

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasAttributedTo wasAttributedTo

https://orcid.org/0000-0002-3668-2627 Elif Ozkan

Elif Ozkan

2022-10-10T14:39:01.856Z

http://purl.org/np/RASraUVoS8... RASraUVoS8

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#generatedAtTime generatedAtTime

2022-10-10T14:39:01.856927

Elif Ozkan

2022-10-10T14:39:01.856Z

http://purl.org/np/RASraUVoS8... RASraUVoS8

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

Maraviroc tablets are indicated in combination with other antiretroviral agents for the treatment of only CCR5-tropic human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients 2 years of age and older weighing at least 10 kg. The drug is available in the US and Europe for adults and children with HIV-1 infection.

Elif Ozkan

2022-10-10T14:39:01.856Z